UK markets closed

EDAP TMS S.A. (EDAP)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
6.84-0.25 (-3.53%)
At close: 04:00PM EDT

EDAP TMS S.A.

Parc dActivites la Poudrette-Lamartine
4/6, rue du DauphinE Vaulx-en-Velin
Lyon 69120
France
33 4 72 153 150
https://www.edap-tms.com

Sector(s)Healthcare
IndustryMedical Distribution
Full-time employees307

Key executives

NameTitlePayExercisedYear born
Mr. Marc OczachowskiExecutive ChairmanN/AN/A1970
Mr. Ryan RhodesCEO & DirectorN/AN/A1962
Mr. Ken MobeckChief Financial OfficerN/AN/A1971
Mr. Carre EmmanuelChief Operating OfficerN/AN/AN/A
Mr. Francois DietschChief Accounting OfficerN/AN/A1976
Ms. Blandine ConfortHead of Legal Affairs & Investor Relations and SecretaryN/AN/AN/A
Mr. Frederic PechPresident of EDAP TMS FranceN/AN/A1969
Mr. Jean-Francois BachelardPresident & Chief Executive Officer of Edaptechnomed Co. Ltd.N/AN/A1964
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. The company operates through High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST) segments. The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. It markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. The company serves hospitals, urology clinics, and research institutions. EDAP TMS S.A. was incorporated in 1979 and is based in Lyon, France.

Corporate governance

EDAP TMS S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.